NCT07449702Phase 2Recruiting

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Study sponsor: Oruka Therapeutics, Inc. · ORKA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-05Estimated
Enrollment · participants240Estimated
Source updated2026-10-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs). After: Measure: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs).

Planned enrollment increased by 160 participants

Before: 80 participants (planned). After: 240 participants (planned).

Primary completion date changed

Before: Nov 2028. After: May 2030.

Check registry source